February panel for Serono's Rebif

The FDA's Peripheral & Nervous System Drugs Advisory Committee will review on Feb. 15, 2002 Serono's BLA for Rebif recombinant interferon beta-1a to treat relapsing-remitting multiple sclerosis (RRMS). Serono (SRA; SWX:SEO) amended the BLA in October to include clinical data from the EVIDENCE (Evidence for Interferon Dose-effect: European-North American Comparative Efficacy) study, a head-to-head comparative trial of Rebif and Avonex interferon beta-1a from Biogen (BGEN) in RRMS patients (see BioCentury, Oct. 15). ...